Skip to main content

Table 1 Patient characteristics at time of diagnosis

From: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer

  Number (%) miRNA-126 expression level
(μm2)
  (n = 89) Median (95% CI) p - value
Sex    
   Male 45 (51) 2533 (1690-3285) 0.84
   Female 44 (49) 2354 (1650-3163)  
Age (years)    
   Mean (SD) 63.2 (8.2)   
   Range 24 - 80   
   > mean 49 (55) 2088 (1556-3223) 0.56
   < mean 40 (45) 2531 (1896-3355)  
ECOG Performance status    
   0 37 (42) 2041 (1551-3163) 0.40
   1-2 52 (58) 2535 (1708-3489)  
Localization    
   Rectum 18 (20) 3038 (1690-4030) 0.37
   Colon 71 (80) 2141 (1650-2638)  
   Left colon 47 (66) 2141 (1589-2818) 0.99
   Right colon 24 (34) 2232 (1452-3355)  
MSI status*    
   MSI 8 (11) 2193 (1374-5421) 0.61
   MSS 62 (89) 2355 (1705-2818)  
Metastatic sites*    
   1 27 (31) 3575 (3163-4521) < 0.0001
≥ 2 59 (69) 1857 (151-2376)  
  1. CI confidence interval, SD standard deviation, ECOG Eastern Cooperative Oncology Group, MSI microsatellite instability, MSS , microsatellite stable
  2. *MSI status was not assessed in all patients
  3. **A reliable estimate of the number of metastatic sites was not possible in 3 patients